TISIDB

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Cell membrane; Single-pass type II membrane protein.; SUBCELLULAR LOCATION: Isoform 3: Cell membrane; Single-pass type II membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm ; SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 11, soluble form: Secreted
Domain	PF00229 TNF(Tumour Necrosis Factor) family
Function	Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy (PubMed:22664871). Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0000187 activation of MAPK activity GO:0001501 skeletal system development GO:0001503 ossification GO:0001659 temperature homeostasis GO:0001660 fever generation GO:0001894 tissue homeostasis GO:0002158 osteoclast proliferation GO:0002521 leukocyte differentiation GO:0002526 acute inflammatory response GO:0002548 monocyte chemotaxis GO:0002573 myeloid leukocyte differentiation GO:0002673 regulation of acute inflammatory response GO:0002675 positive regulation of acute inflammatory response GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002761 regulation of myeloid leukocyte differentiation GO:0002763 positive regulation of myeloid leukocyte differentiation GO:0002790 peptide secretion GO:0002791 regulation of peptide secretion GO:0002793 positive regulation of peptide secretion GO:0006820 anion transport GO:0006869 lipid transport GO:0006953 acute-phase response GO:0007159 leukocyte cell-cell adhesion GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007254 JNK cascade GO:0007257 activation of JUN kinase activity GO:0009914 hormone transport GO:0010720 positive regulation of cell development GO:0010817 regulation of hormone levels GO:0010876 lipid localization GO:0015711 organic anion transport GO:0015718 monocarboxylic acid transport GO:0015732 prostaglandin transport GO:0015833 peptide transport GO:0015908 fatty acid transport GO:0019722 calcium-mediated signaling GO:0019932 second-messenger-mediated signaling GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0023061 signal release GO:0030072 peptide hormone secretion GO:0030099 myeloid cell differentiation GO:0030316 osteoclast differentiation GO:0030595 leukocyte chemotaxis GO:0030879 mammary gland development GO:0031098 stress-activated protein kinase signaling cascade GO:0031349 positive regulation of defense response GO:0031620 regulation of fever generation GO:0031622 positive regulation of fever generation GO:0031649 heat generation GO:0031650 regulation of heat generation GO:0031652 positive regulation of heat generation GO:0032103 positive regulation of response to external stimulus GO:0032147 activation of protein kinase activity GO:0032303 regulation of icosanoid secretion GO:0032305 positive regulation of icosanoid secretion GO:0032306 regulation of prostaglandin secretion GO:0032308 positive regulation of prostaglandin secretion GO:0032309 icosanoid secretion GO:0032310 prostaglandin secretion GO:0032368 regulation of lipid transport GO:0032370 positive regulation of lipid transport GO:0032844 regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0032872 regulation of stress-activated MAPK cascade GO:0032874 positive regulation of stress-activated MAPK cascade GO:0033209 tumor necrosis factor-mediated signaling pathway GO:0033598 mammary gland epithelial cell proliferation GO:0033674 positive regulation of kinase activity GO:0034103 regulation of tissue remodeling GO:0034105 positive regulation of tissue remodeling GO:0034109 homotypic cell-cell adhesion GO:0034110 regulation of homotypic cell-cell adhesion GO:0034112 positive regulation of homotypic cell-cell adhesion GO:0034612 response to tumor necrosis factor GO:0036035 osteoclast development GO:0038001 paracrine signaling GO:0042110 T cell activation GO:0042886 amide transport GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043270 positive regulation of ion transport GO:0043396 corticotropin-releasing hormone secretion GO:0043397 regulation of corticotropin-releasing hormone secretion GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0043491 protein kinase B signaling GO:0043506 regulation of JUN kinase activity GO:0043507 positive regulation of JUN kinase activity GO:0044070 regulation of anion transport GO:0045124 regulation of bone resorption GO:0045453 bone resorption GO:0045637 regulation of myeloid cell differentiation GO:0045639 positive regulation of myeloid cell differentiation GO:0045670 regulation of osteoclast differentiation GO:0045672 positive regulation of osteoclast differentiation GO:0045780 positive regulation of bone resorption GO:0045785 positive regulation of cell adhesion GO:0045860 positive regulation of protein kinase activity GO:0046328 regulation of JNK cascade GO:0046330 positive regulation of JNK cascade GO:0046849 bone remodeling GO:0046850 regulation of bone remodeling GO:0046852 positive regulation of bone remodeling GO:0046879 hormone secretion GO:0046883 regulation of hormone secretion GO:0046887 positive regulation of hormone secretion GO:0046942 carboxylic acid transport GO:0048732 gland development GO:0048771 tissue remodeling GO:0048871 multicellular organismal homeostasis GO:0050673 epithelial cell proliferation GO:0050727 regulation of inflammatory response GO:0050729 positive regulation of inflammatory response GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0050900 leukocyte migration GO:0051047 positive regulation of secretion GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051403 stress-activated MAPK cascade GO:0051466 positive regulation of corticotropin-releasing hormone secretion GO:0051896 regulation of protein kinase B signaling GO:0051897 positive regulation of protein kinase B signaling GO:0055074 calcium ion homeostasis GO:0060249 anatomical structure homeostasis GO:0060326 cell chemotaxis GO:0060348 bone development GO:0060749 mammary gland alveolus development GO:0061180 mammary gland epithelium development GO:0061377 mammary gland lobule development GO:0061515 myeloid cell development GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070304 positive regulation of stress-activated protein kinase signaling cascade GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070374 positive regulation of ERK1 and ERK2 cascade GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0071356 cellular response to tumor necrosis factor GO:0071593 lymphocyte aggregation GO:0071674 mononuclear cell migration GO:0071715 icosanoid transport GO:0071812 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071847 TNFSF11-mediated signaling pathway GO:0071848 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0072507 divalent inorganic cation homeostasis GO:0090087 regulation of peptide transport GO:0090276 regulation of peptide hormone secretion GO:0090277 positive regulation of peptide hormone secretion GO:0097529 myeloid leukocyte migration GO:0098751 bone cell development GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903010 regulation of bone development GO:1903012 positive regulation of bone development GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903532 positive regulation of secretion by cell GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:1903793 positive regulation of anion transport GO:2000191 regulation of fatty acid transport GO:2000193 positive regulation of fatty acid transport GO:2001204 regulation of osteoclast development GO:2001206 positive regulation of osteoclast development
Molecular Function	GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0005164 tumor necrosis factor receptor binding GO:0032813 tumor necrosis factor receptor superfamily binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04064 NF-kappa B signaling pathway hsa04380 Osteoclast differentiation hsa04917 Prolactin signaling pathway
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-5676594: TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway R-HSA-5668541: TNFR2 non-canonical NF-kB pathway R-HSA-5669034: TNFs bind their physiological receptors

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TNFSF11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between TNFSF11 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24752296	Melanoma	Inhibit immunity	We show that in vivo RANKL blockade selectively and transiently depletes Aire and TSA expression in the thymus to create a window of defective negative selection. Furthermore, we demonstrate that RANKL blockade can rescue melanoma-specific T cells from thymic deletion and that persistence of these tumor-specific effector T cells promoted increased host survival in response to tumor challenge.
28634284	Melanoma	Inhibit immunity; Immunotherapy target	Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. RANKL blockade improved the efficacy of anti-CTLA4 mAbs against solid tumors and experimental metastases, with regulatory T-cell (Treg)-depleting anti-CTLA4 mAbs of the mouse IgG2a isotype showing greatest combinatorial activity.
29872559	Melanoma; Prostate Carcinoma; Colon Carcinoma	Inhibit immunity; Resistant to immunotherapy	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. Furthermore, addition of anti-RANKL to anti-PD1 and anti-CTLA4 resulted in superior anti-tumor responses, irrespective of the ability of anti-CTLA4 isotype to engage activating FcR, and concurrent or delayed RANKL blockade was most effective. Early-during-treatment assessment reveals this triple combination therapy compared to dual anti-PD1 and anti-CTLA4 combination therapy further increased the proportion of tumor-infiltrating CD4+ and CD8+ T cells that can produce both IFN-γ and TNF. Finally, RANKL expression appears to identify tumor-specific CD8+ T cells expressing higher levels of PD1 which can be modulated by anti-PD1.
16880256	Multiple myeloma(IgA, IgD, IgE, IgM, IgG)	Inhibit immunity	In this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC-tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing ligand)-mediated interactions.

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TNFSF11 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TNFSF11 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.499	0.364
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.816	0.345
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.286	0.704
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.593	0.0274
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-2.577	0.0212
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.351	0.793
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.263	0.731
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.055	0.96
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.788	0.52
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.088	0.894
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.581	0.509
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.649	0.0144

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TNFSF11 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFSF11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFSF11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFSF11. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFSF11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TNFSF11 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TNFSF11 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TNFSF11
Name	tumor necrosis factor (ligand) superfamily, member 11
Aliases	TRANCE; RANKL; OPGL; CD254; OPTB2; hRANKL2; TNF-related activation-induced cytokine; osteoclast differentiat ......
Chromosomal Location	13q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TNFSF11 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting TNFSF11.

ID	Name	Drug Type	Targets	#Targets
DB00480	Lenalidomide	Small Molecule	CDH5, CRBN, PTGS2, TNFSF11	4
DB06643	Denosumab	Biotech	TNFSF11	1
DB11582	Thiocolchicoside	Small Molecule	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GA ......	18

Browse TNFSF11